Boston Scientific (BSX) EVP Discloses Shares, RSUs and Option Grants

Rhea-AI Filing Summary

Boston Scientific executive Susan O'Connor, EVP, Global Operations, reported her equity holdings in the company. She directly owns 3,885 shares of Boston Scientific common stock. In addition, she holds multiple grants of restricted stock units (RSUs) that each convert into one share of common stock as they vest over time, with various awards continuing to vest annually on the anniversaries of their original grant dates through periods ending between 2026 and 2029.

O'Connor also holds several stock options giving her the right to buy additional Boston Scientific shares at fixed exercise prices ranging from $37.50 to $106.14 per share, with expiration dates from February 2031 through February 2035. These options generally vest in four equal annual installments starting one year after the respective grant dates. The filing reflects her current beneficial ownership and outstanding equity-based compensation.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Connor Padraig Andrew

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/01/2025

3. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Operations

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,885	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2028(1)	Common Stock	3,174(2)	(3)	D
Restricted Stock Units	(4)	02/13/2029(4)	Common Stock	2,002	(3)	D
Restricted Stock Units	(5)	02/14/2027(5)	Common Stock	2,380(6)	(3)	D
Restricted Stock Units	(7)	02/16/2026(7)	Common Stock	905(8)	(3)	D
Restricted Stock Units	(9)	05/02/2026(9)	Common Stock	1,802(10)	(3)	D
Restricted Stock Units	(11)	09/02/2029(11)	Common Stock	4,687	(3)	D
Stock Option (Right to Buy)	(12)	02/17/2031	Common Stock	13,822	$37.5	D
Stock Option (Right to Buy)	(13)	02/16/2032	Common Stock	12,050	$44.19	D
Stock Option (Right to Buy)	(14)	02/14/2033	Common Stock	14,290	$47.28	D
Stock Option (Right to Buy)	(15)	02/12/2034	Common Stock	12,998	$64.99	D
Stock Option (Right to Buy)	(16)	02/13/2035	Common Stock	5,151	$106.14	D

Explanation of Responses:

1. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

2. This amount represents the unvested portion of RSUs awarded on February 12, 2024, which will continue to vest in three remaining installments on the anniversary of the date of grant.

3. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

5. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

6. This amount represents the unvested portion of RSUs awarded on February 14, 2023, which will continue to vest in two remaining installments on the anniversary of the date of grant.

7. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

8. This amount represents the unvested portion of RSUs awarded on February 16, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant.

9. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

10. This amount represents the unvested portion of RSUs awarded on May 2, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant.

11. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on September 2, 2026, the first anniversary of the date of grant.

12. Grant to the reporting person of an option to purchase 13,822 shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

13. Grant to the reporting person of an option to purchase 12,050 shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

14. Grant to the reporting person of an option to purchase 14,290 shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

15. Grant to the reporting person of an option to purchase 12,998 shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

16. Grant to the reporting person of an option to purchase 5,151 shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Remarks:

oconnorpoa.txt

	/s/ Susan Thompson, Attorney-in-Fact	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Boston Scientific (BSX) shares does the reporting executive directly own?

The reporting executive, an EVP, Global Operations at Boston Scientific, directly owns 3,885 shares of the company's common stock.

What restricted stock units (RSUs) are reported in this Boston Scientific (BSX) filing?

The filing lists multiple restricted stock unit awards, each representing a commitment to deliver one share of Boston Scientific common stock. These RSUs vest in four equal annual installments, with grants having vesting schedules beginning on anniversaries of grant dates in February and May 2023, 2024, 2025, 2026, and September 2026.

What stock options does the Boston Scientific (BSX) executive hold and at what exercise prices?

The executive holds several stock options (rights to buy) Boston Scientific common stock: 13,822 shares at $37.5, 12,050 shares at $44.19, 14,290 shares at $47.28, 12,998 shares at $64.99, and 5,151 shares at $106.14.

When do the Boston Scientific (BSX) stock options reported here expire?

The stock options held by the executive expire on 02/17/2031, 02/16/2032, 02/14/2033, 02/12/2034, and 02/13/2035, depending on the specific grant.

How do the RSU vesting schedules work for the Boston Scientific (BSX) executive?

For each RSU grant, shares of common stock are issued in four equal annual installments, typically beginning on the first anniversary of the grant date. Remaining unvested portions continue to vest annually on those anniversaries until fully vested.

What is the executive’s role and relationship to Boston Scientific (BSX)?

The reporting person is an officer of Boston Scientific, serving as EVP, Global Operations. The filing reports her beneficial ownership of company equity as required for insiders.